Cancer/Tumor Profiling

Global Market Trajectory & Analytics

MCP10868

EXECUTIVE ENGAGEMENTS

POOL

872
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

174
Interactions with Platform & by Email

PARTICIPANTS

33
Unique # Participated

VALIDATIONS

12
Responses Validated*

COMPANIES

44
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

165

PAGES

239

EDITION

8

PRICE

USD 4950

CODE

MCP10868


COMPETITIVE METRICS

COMPANY

D S N T

% *

ACT Genomics Co., LTD.

Login Required

Boreal Genomics, Inc.

Login Required

Caris Life Sciences

Login Required

Cellsonics

Login Required

Exact Sciences Corporation

Login Required

Helomics Corporation

Login Required

HTG Molecular Diagnostics, Inc.

Login Required

Illumina, Inc.

Login Required

IMB Dx

Login Required

Lifecode

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 44 COMPETITORS

Login to access data silos

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Cancer/Tumor Profiling estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$11.6 Billion by 2027, growing at a CAGR of 9.3% over the analysis period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hybridization segment is readjusted to a revised 9.7% CAGR for the next 7-year period.
The Cancer/Tumor Profiling market in the U.S. is estimated at US$1.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2 Billion by the year 2027 trailing a CAGR of 8.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$864.8 Million in the year 2020 will reach a projected size of US$1.7 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

SELECT PLAYERS

Caris Life Sciences; Genomic Health, Inc.; Helomics Corporation; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Nanostring Technologies, Inc.; NeoGenomics Laboratories, Inc.; Oxford Gene Technology; Qiagen NV; Ribomed Biotechnologies, Inc.

SEGMENTS

» Application (Clinical Application, Research Application) » Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types) » Technology (Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry, Other Technologies (Pyrosequencing and Sanger Sequencing))

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Cancer/Tumor Profiling: Market Overview & Outlook
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Incidence of Cancer Worldwide: Primary Growth Driver
EXHIBIT: Cancer Rates (100,000 People) in Select Countries: 2021
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
EXHIBIT: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020
The United States: Characterized by Higher Incidence of Cancer
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020
EXHIBIT: Estimated New Cases for Selected Cancers in the US by State: 2020
Enhanced Use of Biomarkers in Tumor Profiling Bodes Well
Cancer Research & Funding Initiatives Augment Market Prospects
Growing Role of Personalized Medicine Augurs Well
Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
China Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
China Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
France Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
France Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027
Total Companies Profiled: 44

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com